Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo.

Cells - 5 Apr 2022

Niessner Heike, Burkard Markus, Leischner Christian, Renner Olga, Plöger Sarah, Meraz-Torres Francisco, Böcker Matti, Hirn Constanze, Lauer Ulrich M, Venturelli Sascha, Busch Christian, Sinnberg Tobias

Abstract excerpt

High-dose ascorbate paradoxically acts as a pro-oxidant causing the formation of hydrogen peroxide in an oxygen dependent manner. Tumor cells (in particular melanoma cells) show an increased vulnerability to ascorbate induced reactive oxygen species (ROS). Therefore, high-dose ascorbate is a promising pharmacological approach to treating refractory melanomas, e.g., with secondary resistance to targeted BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Reactive Oxygen Species

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 35406796
DOI: 10.3390/cells11071229
PMCID: PMC8997901

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo.PMID 35406796Read ↗

Vitamin C (Ascorbate) and Redox Topics in CancerSemantic proximity Read ↗

Ascorbate induces apoptosis in melanoma cells by suppressing Clusterin expressionSemantic proximity Read ↗

Radiosensitisation by pharmacological ascorbate in glioblastoma multiforme cells, human glial cells, and HUVECs depends on their antioxidant and DNA repair capabilities and is not cancer specificSemantic proximity Read ↗

ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cellsSemantic proximity Read ↗

Selective ascorbate toxicity in malignant mesothelioma: a redox Trojan mechanism.Semantic proximity Read ↗

Ascorbic Acid Therapy in Hematological Malignancies - The Current Knowledge and Future DirectionsSemantic proximity Read ↗

Potential Mechanisms of Action for Vitamin C in Cancer: Reviewing the EvidenceSemantic proximity Read ↗

Vitamin C selectively kills <i>KRAS</i> and <i>BRAF</i> mutant colorectal cancer cells by targeting GAPDHSemantic proximity Read ↗

Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells.Semantic proximity Read ↗

Advantages of Vitamin C Anticancer Therapy over Other Pharmacological InterventionsSemantic proximity Read ↗

Vitamin C administration by intravenous infusion increases tumour ascorbate content in patients with colon cancer: a clinical intervention studySemantic proximity Read ↗

Ascorbic Acid in Colon Cancer: From the Basic to the Clinical Applications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.